Elevated serum prolactin levels as a marker of inflammatory arthritis in psoriasis vulgaris
Open Access
- 3 December 2015
- journal article
- Published by Palacky University Olomouc in Biomedical Papers
- Vol. 159 (4) , 562-568
Abstract
Psoriasis vulgaris (PV) is complicated in up to 40% patients by the inflammatory joint disease psoriatic arthritis (PsA). Neither the aetiology of the arthritis nor specific laboratory markers for its disease activity have been clearly elucidated. Prolactin (PRL) acts as a cytokine with immunomodulatory functions and plays a role in skin and joint biology. The results on PRL however as a marker are unclear. The aim of this study was to confirm whether serum PRL levels reflect systemic complications of PV, like inflammatory joint disease and/or can serve as a marker of disease activity in both cases. A total of 70 patients with PV without arthritis and 40 patients suffering from PsA were included. In all patients, we determined skin disease activity according to the PASI index and in PsA, active disease assessed as swollen or tender joints. The control group included 27 age and sex matched healthy individuals. The concentration of PRL in the serum was measured by immunoradiometric assays. The PRL serum levels were significantly increased in PsA patients (299.2±28.29 mIU/L) compared to PV only patients (201.4.2±11.72 mIU/L), P = 0.0003 and healthy individuals (198.2±15.31 mIU/L), P = 0.007. The serum PRL levels in PsA with active disease 336.8±42.50 (mIU/L) were higher than in PV and controls, P < 0.0001 and P = 0.002 respectively. In PV only patients, there was no correlation between PASI and PRL levels. Our results showed that PRL serum levels are a marker of active arthritis in PsA and reflects systemic complication rather than local skin activity.Keywords
This publication has 31 references indexed in Scilit:
- Activity of the neuroendocrine axes in patients with polymyalgia rheumatica before and after TNF-α blocking etanercept treatmentArthritis Research & Therapy, 2012
- Impaired Expression of Tim-3 on Th17 and Th1 Cells in PsoriasisActa Dermato-Venereologica, 2012
- Update on Biomarkers in Psoriatic Arthritis: A Report from the GRAPPA 2010 Annual Meeting: Table 1.The Journal of Rheumatology, 2012
- Clinical efficacy of propylthiouracil and its influence on prolactin in psoriatic patientsClinical Biochemistry, 2011
- Circulating levels of interleukin-6, vascular endothelial growth factor, YKL-40, matrix metalloproteinase-3, and total aggrecan in spondyloarthritis patients during 3 years of treatment with TNFα inhibitorsClinical Rheumatology, 2010
- Interplay between keratinocytes and immune cells—Recent insights into psoriasis pathogenesisThe International Journal of Biochemistry & Cell Biology, 2009
- Molecular transduction mechanisms of cytokine hormone interactions: role of gp130 cytokinesExperimental Physiology, 2007
- Improvement of ACTH response to insulin tolerance test in female patients with rheumatoid arthritis due to tumor necrosis factor inhibitionEuropean Journal of Endocrinology, 2007
- Spotlight on the role of hormonal factors in the emergence of autoreactive B-lymphocytesImmunology Letters, 2005
- The prevalence of psoriasis in African Americans: Results from a population-based studyJournal of the American Academy of Dermatology, 2005